STOCK TITAN

MACROGENICS (MGNX) SEC Filings

MGNX NASDAQ

MacroGenics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics, including DART molecules and antibody-drug conjugates. Current reports record financial and operating results, FDA-related updates for the LINNET study of lorigerlimab, and material agreements involving ZYNYZ royalty rights under the Incyte collaboration.

Proxy and governance filings cover board elections, executive compensation, director matters and officer transitions. The filing record also addresses capital resources, collaboration and license economics, clinical-development disclosures, product-candidate updates and stockholder voting matters.

Rhea-AI Summary

MacroGenics, Inc. (MGNX) is the issuer in an amended beneficial-ownership report by Armistice Capital, LLC and Steven Boyd, the investment manager and managing member, respectively. As of September 30, 2026, each reported beneficial ownership of 6,000,000 common shares, or 9.42%, with shared voting and dispositive power and no sole voting or dispositive power.

Armistice Capital Master Fund Ltd. is the direct holder and has the right to dividends and sale proceeds. Armistice Capital exercises voting and investment power under an investment management agreement; the Master Fund disclaims beneficial ownership because it cannot vote or dispose of the shares under that agreement. Boyd may be deemed to beneficially own the same securities through his role at Armistice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
ownership
-
Rhea-AI Summary

MacroGenics, Inc. (MGNX) made an updated corporate presentation available, with clinical program details current as of November 12, 2026. It reported $288 million in cash equivalents and marketable securities as of September 30, 2026, cash runway guidance through 2028, and $359 million in non-dilutive capital generated during 2025–26.

For MGC026, the Stage 1 squamous cell carcinoma of the head and neck (SCCHN) cohort had a best overall response rate of 27.3% (6/22), confirmed response rate of 18.2% (4/22), and disease control rate of 63.6% (14/22). In the separate 7.5 mg/kg SCCHN expansion safety group (27 participants), 13 (48.1%) had grade 3 or higher treatment-related adverse events; none discontinued treatment because of such events. The data cutoff was September 1, 2026, and results were not final and subject to change.

MacroGenics also reported completing MGC028 Phase 1 dose escalation with no dose-limiting toxicities, interstitial lung disease or ocular toxicity reported; an interim update was anticipated in the first half of 2027. The first participant had been dosed in the MGC030 Phase 1 study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
current report
-
Rhea-AI Summary

MacroGenics (MGNX) reported third-quarter 2026 revenue of $18.7 million, compared with $53.0 million a year earlier, and a net loss of $20.1 million versus net income of $16.8 million. Revenue included $10.0 million related to Gilead’s option exercise, compared with $50.0 million of milestone revenue recognized in 2025; a $5.3 million increase in ZYNYZ royalty revenue partly offset the decrease. Cash, cash equivalents and marketable securities were $287.7 million as of September 30, 2026, compared with $189.9 million as of December 31, 2025. Third-quarter receipts included $119.6 million from Bora related to the sale of GMP manufacturing operations and a $24.5 million Sanofi regulatory milestone. MacroGenics expects its cash and projected and anticipated future partner payments to support runway through 2028.

The company completed MGC028 Phase 1 dose escalation, selected a lead indication and plans to initiate a randomized evaluation of two dose levels in that indication by year end 2026; as of October 10, 2026, no dose-limiting toxicities, ILD or ocular toxicity were reported. MGC030’s first Phase 1 patient was dosed. MGC026 enrollment completion is expected by year end 2026, with updated data expected in mid-2027; updated lorigerlimab results are expected in the first half of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.93%
Tags
current report
Rhea-AI Summary

MacroGenics, Inc. (MGNX) reported third-quarter and nine-month 2026 results and completed the sale of its CDMO operations to Bora, effective June 30, 2026. Third-quarter revenue was $18.7 million versus $53.0 million a year earlier, and net loss was $20.1 million compared with net income of $16.8 million. For the nine months, revenue was $58.2 million versus $66.9 million, while continuing-operations loss was $132.4 million versus $75.9 million. Operating cash used was $82.9 million, compared with $124.1 million in the prior-year period.

Bora paid $119.6 million in July 2026, subject to customary post-closing adjustments for working capital and indebtedness; MacroGenics recognized an $87.5 million net gain after transaction costs. The sale marks an exit from contract manufacturing, with the company focusing resources on its preclinical and clinical-stage pipeline. Nine-month royalty revenue was $22.1 million, compared with $5.1 million in 2025, primarily due to higher ZYNYZ sales. Gilead paid $10.0 million in August 2026 after exercising its option for a license to the First Research Program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.93%
Tags
quarterly report
-
Rhea-AI Summary

MacroGenics (MGNX) director Michael Vasconcelles received awards of 44,000 stock options and 7,500 restricted stock units on October 30, 2026. The options have a $2.40 exercise price and vest in monthly, cumulative 1/36th increments, rounded up to whole shares, beginning one month after grant; they expire October 30, 2036. Each restricted stock unit represents a contingent right to one common share and vests 33% one year after grant and 33% each year thereafter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
insider
Rhea-AI Summary

MacroGenics Inc. director Emil Kuriakose received a stock option covering 44,000 common shares, with a $2.40 exercise price, and 7,500 restricted stock units on October 30, 2026. The option vests in monthly, cumulative 1/36th increments beginning one month after grant and expires October 30, 2036. Each RSU represents a contingent right to one common share; 33% vest one year after grant and 33% each year thereafter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
insider
-
Rhea-AI Summary

MacroGenics, Inc. approved an increase in its board size from 10 to 11 members and appointed Michael Vasconcelles as a Class II Director and Emil Kuriakose as a Class III Director, effective October 30, 2026. The board determined both are independent and appointed them to its Science and Technology Committee.

Each director will receive an annual retainer and, upon appointment, an option to purchase 44,000 shares and a restricted stock unit grant for 7,500 shares. Each option’s exercise price equals the common stock’s closing market price on the effective date. Both awards are subject to continuous service through their vesting dates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
current report
Rhea-AI Summary

MacroGenics reported interim Phase 1 results for MGC026, with a 27.3% best overall response rate (6/22) among response-evaluable patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Four responses were confirmed and two unconfirmed; disease control rate was 63.6% (14/22). Five of 16 HPV-positive patients responded (31.3%). The data cutoff was September 1, 2026.

Among 27 SCCHN patients evaluable for safety, grade ≥3 treatment-related adverse events occurred in 48.1% (13/27), with no treatment-related discontinuations; no interstitial lung disease, pneumonitis or ocular toxicity was observed. In dose escalation, 17 response-evaluable patients treated at ≥6 mg/kg had a confirmed objective response rate of 29% (5/17), disease control rate of 65% (11/17) and median duration of response of 10.2 months. The interim results were subject to change.

MacroGenics plans to initiate a front-line SCCHN cohort combining MGC026 with pembrolizumab in early 2027 for patients with PD-L1-positive disease (CPS ≥1). Enrollment continues in the ongoing monotherapy cohort; updated data are expected in mid-2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
current report

FAQ

How many MACROGENICS (MGNX) SEC filings are available on StockTitan?

StockTitan tracks 84 SEC filings for MACROGENICS (MGNX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for MACROGENICS (MGNX)?

The most recent SEC filing for MACROGENICS (MGNX) was filed on November 16, 2026.